Digital health is the use of digital platforms, such as mobile phones and wearable devices, to bring healthcare directly to the patient and provide medical treatment that focuses on the personalized needs of the individual. This personalized approach to healthcare is particularly important for the optimization of clinical trials in psychiatry.
Psychiatric populations are highly heterogeneous, both in terms of symptom severity and cognitive ability. Therefore, when testing a new compound designed to alleviate psychiatric symptoms or exert pro-cognitive effects, it is vitally important to consider the individual variability of the clinical population. In the past, these considerations have often not been accounted for and drug efficacy may have gone undetected as a result.
In this webinar, Director of Digital Neuroscience at Cambridge Cognition, Dr Nathan Cashdollar, and Senior Director of Product Innovation at ICON PLC, Marie McCarthy, will navigate you through the new field of digital health in psychiatry, to conclude which technologies look to be most promising for optimizing clinical trials, and how to successfully operationalize these digital solutions.
Nathan Cashdollar, PhD, Director of Digital Neuroscience, Cambridge Cognition
With over a decade of experience in both academic and clinical research, Nathan is an expert in the development of scientifically valid and clinically sensitive digital solutions for measuring cognitive performance in healthcare and clinical trial research environments. In his current role at Cambridge Cognition, Nathan provides comprehensive scientific consultancy and potentiates the development of digital innovations for clinical trial experimentation in order to optimize outcomes.Message Presenter
Marie McCarthy, MBA, Senior Director of Product Innovation, ICON PLC
Within the multidisciplinary Innovation Team at ICON PLC, Marie is responsible for developing solutions in the direct-to-patient paradigm. Here the primary focus is on the use of wearables and sensors to collect clinically sensitive endpoints in non-clinical settings, such as the patient home. In her previous role at Philips Respironics, Marie built awareness of the value of Actigraphy endpoints as objective measures of clinical change among clinicians and researchers.
Who Should Attend?
Biopharmaceutical researchers and CRO professionals who are working to develop and commercialize patient-centric clinical trials by leveraging the latest technological advancements, particularly those working in:
- Research and development
- Drug development
- Medical affairs
- Market access
- Patient engagement
- Digital health
What You Will Learn
- How digital health can streamline clinical trial workflow and enrich overall trial quality
- Overcoming the key challenges, and maximising the benefits of measuring cognition remotely with mobile digital health apps
- Optimizing the use of active and passive digital cognitive biomarkers in clinical trials to conduct patient-centered virtual research
- Leveraging the latest advances in biological sensory technology for remote devices to conduct high-frequency, naturalistic assessments at scale
Cambridge Cognition is a neuroscience digital health company which develops & markets gold standard medical software products and expert scientific services to accelerate the development of safe and effective treatments and quantify cognitive health in patients worldwide.
The company provides products and services to the world’s leading pharmaceutical and biotech companies as well as globally renowned academic institutions.